All In Biotech

Drug Trial Radar · NCT07174583

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

262

Planned (sponsor's estimate)

Start

Oct 14, 2025

Primary completion

Jul 2029

Study completion Jul 2029

Sponsor

Lead sponsor
IDEAYA BiosciencesIndustry
Sponsor type
Industry
First posted
Sep 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Conditions

  • Small-cell Lung Cancer
  • Neuroendocrine Carcinomas
  • Solid Tumor Show to Express DLL3

Interventions

  • IDE849Drug

    IV administration

  • durvalumabDrug

    IV administration

  • IDE161Drug

    oral administration

  • CarboplatinDrug

    IV administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1A: Safety and Tolerability of IDE849 (Monotherapy)Time frame: approximately 4 years total study duration
  2. Part 1B: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161Time frame: approximately 4 years total study duration
  3. Part 2: Safety and Tolerability of IDE849 (Monotherapy Dose Expansion)Time frame: approximately 4 years total study duration
  4. Part 2: Safety and Tolerability of IDE849 in Combination with durvalumab or IDE161 or durvalumab + carboplatin (Dose Expansion)Time frame: approximately 4 years total study duration
  5. Part 2: Objective Response Rate (ORR) and Investigator Assessment of IDE849 ORR per RECIST 1.1Time frame: approximately 4 years total study duration
  6. Part 2: Duration of Response (DOR) and Investigator Assessment of IDE849 DOR per RECIST 1.1Time frame: approximately 4 years total study duration

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado · Recruiting

  • Sarah Cannon Research Institute at Florida Cancer Specialists

    Orlando, Florida · Recruiting

  • Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne North Office

    Fort Wayne, Indiana · Recruiting

  • START Midwest

    Grand Rapids, Michigan · Recruiting

  • The Cancer and Hematology Centers

    Grand Rapids, Michigan · Recruiting

  • Columbia University Medical Center - Herbert Irving Pavilion

    New York, New York · Recruiting

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute - Oncology Partners

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Oncology Consultants, PA- Houston

    Houston, Texas · Recruiting

  • Next Oncology Dallas

    Irving, Texas · Recruiting

  • NEXT Oncology Virginia

    Fairfax, Virginia · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.